Chavda Nilesh, Kantharia N D
Department of Pharmacology, Government Medical College, Surat, India.
J Pharmacol Pharmacother. 2011 Jan;2(1):11-6. doi: 10.4103/0976-500X.77091.
To study the anti-inflammatory activity of fluoxetine and escitalopram in newly diagnosed patients of depression and also to evaluate the association between depression and inflammation.
Ninety-eight newly diagnosed patients of depression were recruited as cases. From these, 48 had started treatment with fluoxetine (20 mg/day) and 50 had started treatment with escitalopram (20 mg/day). After 2 months of treatment of these patients, Hamilton rating scale for depression (HRSD scale), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell (WBC) count were measured and compared to their respective baseline values before starting treatment. One hundred healthy volunteers were recruited as controls and their baseline of CRP, ESR and WBC count were measured and compared with their respective baseline values of cases. Severity of depression was measured by HRSD scale and anti-inflammatory activity was measured by reduction CRP, ESR and WBC count.
On baseline comparison between cases and controls, there were significant increases in the levels of CRP (P = 0.014), ESR (P = 0.023) and WBC count (P = 0.020) in cases. In fluoxetine (20 mg/day) treatment group, there was a significant reduction in the levels of CRP (P = 0.046), ESR (P = 0.043) and WBC count (P = 0.021) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.190). Similarly, in escitalopram treatment group, there was a significant reduction in CRP (P = 0.041), ESR (P = 0.030) and WBC count (P = 0.017) after 2 months of treatment but no significant reduction in HRSD scale (P = 0.169).
In newly diagnosed patients of depression, inflammatory markers such as CRP, ESR and WBC count were significantly raised and Selective serotonin reuptake inhibitors SSRIs such as fluoxetine and escitalopram reduced them independent of their antidepressant effect. So, SSRIs have some anti-inflammatory activity independent of their antidepressant action.
研究氟西汀和艾司西酞普兰对新诊断抑郁症患者的抗炎活性,并评估抑郁症与炎症之间的关联。
招募98例新诊断的抑郁症患者作为病例组。其中,48例开始使用氟西汀(20毫克/天)治疗,50例开始使用艾司西酞普兰(20毫克/天)治疗。对这些患者进行2个月治疗后,测量汉密尔顿抑郁评定量表(HRSD量表)、C反应蛋白(CRP)、红细胞沉降率(ESR)和白细胞(WBC)计数,并与治疗开始前各自的基线值进行比较。招募100名健康志愿者作为对照组,测量其CRP、ESR和WBC计数的基线值,并与病例组各自的基线值进行比较。通过HRSD量表测量抑郁严重程度,通过CRP、ESR和WBC计数的降低来测量抗炎活性。
病例组与对照组的基线比较显示,病例组的CRP水平(P = 0.014)、ESR水平(P = 0.023)和WBC计数(P = 0.020)显著升高。在氟西汀(20毫克/天)治疗组中,治疗2个月后CRP水平(P = 0.046)、ESR水平(P = 0.043)和WBC计数(P = 0.021)显著降低,但HRSD量表无显著降低(P = 0.190)。同样,在艾司西酞普兰治疗组中,治疗2个月后CRP(P = 0.041)、ESR(P = 0.030)和WBC计数(P = 0.017)显著降低,但HRSD量表无显著降低(P = 0.169)。
在新诊断的抑郁症患者中,CRP、ESR和WBC计数等炎症标志物显著升高,氟西汀和艾司西酞普兰等选择性5-羟色胺再摄取抑制剂(SSRI)可使其降低,且与它们的抗抑郁作用无关。因此,SSRI具有一些独立于其抗抑郁作用的抗炎活性。